Mylan says EpiPen supply levels may vary at U.S. pharmacies

NEW YORK (Reuters) - Drugmaker Mylan NV said on Tuesday that supply levels of its EpiPen emergency allergy treatment may vary in the U.S., months after flagging manufacturing issues of the product with U.S. regulators.